Literature DB >> 15128406

Plasticity of somatostatin and somatostatin sst2A receptors in the rat dentate gyrus during kindling epileptogenesis.

Zsolt Csaba1, Cristina Richichi, Véronique Bernard, Jacques Epelbaum, Annamaria Vezzani, Pascal Dournaud.   

Abstract

Increasing evidence suggests that somatostatin may control neuronal excitability during epileptogenesis. In the hippocampus, sst2A receptors are likely to mediate somatostatin inhibitory actions but little is known about their status in kindled tissues. In the present study, sst2A receptor and somatostatin immunoreactivity were examined by confocal microscopy in the hippocampus during and after kindling acquisition. In control rats, somatostatin-positive axon terminals were mainly found in the stratum lacunosum moleculare of CA1 area and in the outer molecular layer of the dentate gyrus. sst2A receptor immunoreactivity was diffusely distributed in the strata radiatum and oriens of CA1 and in the stratum moleculare of the dentate gyrus. Immunogold electron microscopy revealed that sst2A receptors were predominantly localized postsynaptically, at the plasma membrane of dendritic shafts and spines of principal neurons. During kindling epileptogenesis, qualitative and semiquantitative analysis revealed a progressive decrease of sst2A immunoreactivity in the outer molecular layer, which was spatially associated with an increase in somatostatin immunoreactivity. No obvious changes in sst2A receptor immunoreactivity were observed in other hippocampal subfields. These results suggest that the decrease of sst2A receptor immunoreactivity in the outer molecular layer reflects receptor down-regulation in distal dendrites of granule cells in response to chronic somatostatin release. Because the sst2A receptor appears to mediate anticonvulsant and antiepileptogenic effects of somatostatin, this may represent a pivotal mechanism contributing to epileptogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128406     DOI: 10.1111/j.0953-816X.2004.03361.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  7 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Octreotide ameliorates inflammation and apoptosis in acute and kindled murine PTZ paradigms.

Authors:  M Y Al-Shorbagy; Noha N Nassar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-10-01       Impact factor: 3.000

Review 3.  Somatostatin: an endogenous antiepileptic.

Authors:  Melanie K Tallent; Cuie Qiu
Journal:  Mol Cell Endocrinol       Date:  2007-12-14       Impact factor: 4.102

4.  Somatostatin and neuropeptide Y neurons undergo different plasticity in parahippocampal regions in kainic acid-induced epilepsy.

Authors:  Meinrad Drexel; Elke Kirchmair; Anna Wieselthaler-Hölzl; Adrian Patrick Preidt; Günther Sperk
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

5.  Trans-Modulation of the Somatostatin Type 2A Receptor Trafficking by Insulin-Regulated Aminopeptidase Decreases Limbic Seizures.

Authors:  Dimitri De Bundel; Assia Fafouri; Zsolt Csaba; Ellen Loyens; Sophie Lebon; Vincent El Ghouzzi; Stéphane Peineau; Guilan Vodjdani; Foteini Kiagiadaki; Najat Aourz; Jessica Coppens; Laura Walrave; Jeanelle Portelli; Patrick Vanderheyden; Siew Yeen Chai; Kyriaki Thermos; Véronique Bernard; Graham Collingridge; Stéphane Auvin; Pierre Gressens; Ilse Smolders; Pascal Dournaud
Journal:  J Neurosci       Date:  2015-08-26       Impact factor: 6.167

6.  The somatostatin 2A receptor is enriched in migrating neurons during rat and human brain development and stimulates migration and axonal outgrowth.

Authors:  Virginia Le Verche; Angela M Kaindl; Catherine Verney; Zsolt Csaba; Stéphane Peineau; Paul Olivier; Homa Adle-Biassette; Christophe Leterrier; Tania Vitalis; Julie Renaud; Bénédicte Dargent; Pierre Gressens; Pascal Dournaud
Journal:  PLoS One       Date:  2009-05-12       Impact factor: 3.240

Review 7.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.